Foundation Medicine Q3 Revenues Rise 16 Percent, Net Loss Widens

Nov 02, 2016

|

This article has been updated with information and comments from Foundation Medicine's earnings conference call.

NEW YORK (GenomeWeb) – Foundation Medicine reported after the close of the market on Wednesday that third quarter revenues rose 16 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Foundation Medicine Q3 Revenues Rise 16 Percent, Net Loss Widens

To read the full story....

Breaking News

AMP Cautions Against Using Cycle Threshold Values for PCR SARS-CoV-2 Tests in Clinical Practice

Prevencio, Atlas Genomics to Commercialize Cardiac Blood Tests

DiaSorin, Qiagen Obtain CE Mark for Lyme Disease Early Detection Test

Sherlock Bio Foundation Licenses CRISPR Tech to Cooper International, United PPE for COVID-19 Tests

FDA Grants EUA to Enzo Biochem Sample Collection Kit for COVID-19 Testing

Qiagen Nabs CE Mark for High-Throughput SARS-CoV-2 Test Kit

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

What's Popular?

Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer

European Union to Review Illumina's Planned Grail Acquisition Under New Guidance

Prostate Cancer Study Shows Oncotype DX GPS Test Accurately Measures Long-Term Outcomes

PixCell Medical, Axonlab Ink European Distribution Deal for Point-of-Care Hematology Analyzer

Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC

Sponsorships